ST Robotics Reports They Are Increasing Their Laboratory Robotics Production to Meet Demand from COVID-19

DOORwaY-90 Study for SIR-Spheres® Therapy as 1st-line Treatment for Hepatocellular Carcinoma Enrolls First Patient

The study will assess the duration of response (DoR) and objective response rate (ORR) of SIR-Spheres. It is being led by co-principal investigators Cheenu Kappadath, PhD and Dr. Armeen Mahvash.

Global Surgical Lasers Market to Reach $10.1 Billion by 2027

1 Billion by 2027, growing at a CAGR of 9.7% over the analysis period 2020-2027. Solid-State Laser Systems, one of the segments analyzed in the report, is projected to record a 9.2% CAGR and reach US$3.9 Billion by the end of the analysis period.

Carestream Health Advances X-ray Image Quality with Smart Noise Cancellation

SNC has received FDA 510(k) Clearance and is available as an optional feature with Carestream’s ImageView Software powered by Eclipse—the intelligent image-processing engine behind the company’s innovative imaging software—on DRX-Evolution and DRX-Evolution Plus systems.

Today ST Robotics reported they are ramping up its shipments of four, five and six-axis industrial robots, in response to the recent increase in demand from COVID-19.

ST Robotics notes that Mesa Labs in Montana is using the ST Robotics systems to increase production and maximize flexibility for the vapor hydrogen peroxide sterilization of its Apex biological indicator (BI) products.  To meet their client demands in the fight against COVID-19, Mesa Labs is in the process of implementing another ST robotic arm that is specifically designed for a medical device manufacturer of personal protective equipment (PPE).

“By using ST Robots, we save 22 hours of direct labor per day.   ST Robotics is wonderful to work with and their products have been a great investment for our product lines,” commented Nicholas Spain, Mesa Labs Senior Manager of Manufacturing.

ST Robotics has been a successful producer in laboratory robotics since 1993.  Their customers include major pharmaceutical companies and research institutes, including the National Institutes of Health (NIH), the Wellcome Sanger Institute, Pfizer, GlaxoSmithKline (GSK), and Eli Lilly.  ST Robotics improves the automation of everything from polymerase chain reaction (PCR) to high-throughput screening in forensic science, drug development, bacterial resistance, toxicology, stem cell research, and other fields.  The UK Forensic Science Service set up the largest national DNA database in the world using eight ST robots.

“Even today, we are still able to solve those difficult laboratory automation problems that no-one else can solve,” says David Sands, Founder CEO at ST Robotics. “Moreover, because of our vast experience in the demanding world of manufacturing, we can offer the lab market a totally reliable workhorse of a robot, together with software and hardware that enables us to interface with any other instruments or devices.”  Sands also founded the European branch of the Laboratory Robotics Interest Group (ELRIG) in 2001.

According to a new report by Market Watch, The Global Lab Automation Market is expected to exceed more than US$ 8 Billion by 2027 at a CAGR of 6.5%.

spot_img

DON'T MISS

Subscribe to Medical Device News Magazine here.

Related Articles